Bispecific agents: the future of AML and MDS treatment?
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
Promising treatment options for relapsed, low grade lymphoma
Next steps in gaining CLARITY on CLL